All Studies All Outcomes

A Study of Brexanolone for Acute Respiratory Distress Syndrome Due to COVID-19

Brown et al., NCT04537806, NCT04537806

Jul 2022

Post
Facebook

Source PDF All Studies Meta AnalysisMeta

Download Image

RCT 28 ventilated patients, showing no significant difference with brexanolone treatment.

Important missing comments or errors? Let us know.

risk of death, 14.3% higher, RR 1.14, p = 1.00, treatment 8 of 14 (57.1%), control 7 of 14 (50.0%), day 40.

risk of death, 33.3% higher, RR 1.33, p = 0.71, treatment 8 of 14 (57.1%), control 6 of 14 (42.9%), day 28.

respiratory failure or death, no change, RR 1.00, p = 1.00, treatment 10 of 14 (71.4%), control 10 of 14 (71.4%), day 28.

Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates

Brown et al., 27 Jul 2022, Double Blind Randomized Controlled Trial, placebo-controlled, USA, preprint, 1 author, trial NCT04537806 (history). Contact: info@sagerx.com.

This Paper Brexanolone All

Late treatment
is less effective

Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.

Submit

Post

@CovidAnalysis

FAQ

Public domain CC0 1.0